Viatris Reveals Next Steps For Once-Monthly US Copaxone Rival After Rejection
CRL Disclosed In March Pushed Back Key Opportunity; Working With Partner Mapi
Executive Summary
Viatris has revealed the early stages of a battle plan after it was knocked back on US FDA approval for its proposed once-monthly glatiramer acetate ‘GA Depot’ product, a follow-on to Teva’s Copaxone treatment for relapsing forms of multiple sclerosis.